PMC:7195088 / 23182-23357
Annnotations
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T114 | 166-174 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T114 | 53-57 | http://purl.obolibrary.org/obo/CLO_0008416 | denotes | peer |
T115 | 53-57 | http://purl.obolibrary.org/obo/CLO_0050081 | denotes | peer |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T275 | 88-99 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T276 | 104-115 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T277 | 120-131 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T278 | 137-148 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T171 | 0-175 | Sentence | denotes | The manuscript is publicly available but still to be peer reviewed [30] • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. |